Another AIM listing for the KISS Creative Group


Cambridge and London based creative communications agency, KISS has successfully completed a strategic, digital and marketing project to help prepare IXICO Limited for its proposed reverse takeover of Phytopharm Plc and admission to the Alternative Investment Market (“AIM”) of the London Stock Exchange.

IXICO Limited brings innovative technologies to those involved in researching and treating serious diseases enabling them to help patients quicker. KISS won the integrated marketing project following a three-way pitch and the project kicked off with a series of three KISS strategy workshops, including re-positioning of the brand, strategy, proposition, and products.  Following these, KISS is involved in a two-phase website project.  The first phase consists of the development of a fully responsive corporate site that went live on 10 September with other projects and developments in the pipeline.

Kate McLeish, VP Technology, said: “We choose KISS as the agency has a solid reputation in the science and technology sector and experience of working with businesses looking for significant growth.  KISS has impressed us throughout the journey and we look forward to an on-going relationship with the KISS team.”

John Dibb, Head of Digital at KISS said: “IXICO is a great example of how fully integrated marketing can help support a business achieve its objectives and drive growth. We have worked hard to challenge and surprise IXICO with the site design and simplicity of the CMS. The site is fully responsive with integrated social media that alerts users on how many tweets, shares and posts they have missed since their last visits.”

Simon Fryer, CEO at KISS said: We understand the complexities and requirements of clients going through considerable change, whether entering new markets, creating new brands or to their corporate structure, for fund raising, listing, mergers and acquisitions or plain old growth. We are fortunate to work with a wide range of companies listed on the main market, AIM and Private Equity owned and VC backed businesses and over the years we have strengthened our team, processes and procedures to be agile and inject pace in everything we do.  We wish the IXICO team every success as they take the next step on their journey.”

KISS was recently named in Business Weekly’s Cambridge Business Leaderboard as one of a handful of visionary companies that are acting as pathfinders to better times.  The agency joined 26 other strategic pioneers in Cambridge, some of which are KISS clients, separating themselves from their competitors by identifying new business models and innovative ways of working.

 

For all the latest KISS news, do follow us on Twitter (http://twitter.com/KISStalk) and LinkedIn.

 

—ends—

Notes to Editor:

 About KISS www.kisscom.co.uk

 

The KISS Creative Group is built on the philosophy of keeping things simple. Our mission is to surprise our clients with ideas that inspire.

Our clients include Anglian Water, Bayer CropScience, Bokomo Foods UK, PlastiKote, Booking.com, Johnson Matthey, Bosch, and successful SMEs including IMServ, IXICO, Cambridge Cognition, Bidwells, One Nucleus, Horizon Discovery, IMRG, 8 Solutions, PWR+, PraxisUnico, SBRI Healthcare, Real-Status, Intergence, Snap-on Industrial  and Cambridge Past, Present & Future.

The KISS Creative Group comprises KISS Communications, KISS Public Relations and KISS Digital.  We provide strategy, advertising, design, branding, digital, exhibition, public relations and social media services.

For further information, please contact:

Laura Brown

T: 01223 911 123 or 0208 12345 75

email

 

 

About IXICO www.ixico.com

 

IXICO was founded in 2004 with a mission to translate image acquisition, management and analysis technology and know-how, which the founders had developed together, into commercial products targeting the expanding area of imaging to inform decision-making during drug development. This has resulted in commercially successful products being launched in the clinical trials (Phase 0-III) and experimental medicine markets and being readied for launch into the wider clinical diagnostic market. Since incorporation, IXICO has been contracted by seven of the top 15 global pharmaceutical companies as well as leading biotechnology companies.

 

Comments are closed.